How to buy Co-Diagnostics stock | $12.12

Co-Diagnostics, Inc is a diagnostics & research business based in the US. Co-Diagnostics shares (CODX) are listed on the NASDAQ and all prices are listed in US Dollars. Co-Diagnostics employs 39 staff and has a trailing 12-month revenue of around USD$47.5 million.

How to buy shares in Co-Diagnostics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Co-Diagnostics. Find the stock by name or ticker symbol: CODX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Co-Diagnostics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$12.12, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Co-Diagnostics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Co-Diagnostics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Co-Diagnostics share price

Use our graph to track the performance of CODX stocks over time.

Co-Diagnostics shares at a glance

• Key figures

Information last updated 2021-01-14.

Latest market close	USD$12.12
52-week range	USD$1.07 - USD$29.99
50-day moving average	USD$10.6867
200-day moving average	USD$14.5409
Wall St. target price	USD$31
PE ratio	9.082
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$1.122

Buy Co-Diagnostics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Co-Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Co-Diagnostics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Co-Diagnostics price performance over time

Historical closes compared with the close of $12.12 from 2020-10-22

1 week (2021-01-08)	9.98%
1 month (2020-12-16)	13.59%
3 months (2020-10-16)	-13.43%
6 months (2020-07-16)	-35.87%

1 year (2020-01-16)	1,043.40%
2 years (2019-01-16)	1,012.03%
3 years (2018-01-16)	305.35%
5 years (2016-01-12)	N/A

Is Co-Diagnostics under- or over-valued?

Valuing Co-Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Co-Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Co-Diagnostics's P/E ratio

Co-Diagnostics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Co-Diagnostics shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Co-Diagnostics's EBITDA

Co-Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$24.1 million.

The EBITDA is a measure of a Co-Diagnostics's overall financial performance and is widely used to measure a its profitability.

Co-Diagnostics financials

Revenue TTM	USD$47.5 million
Operating margin TTM	50.6%
Gross profit TTM	USD$102,543
Return on assets TTM	51.4%
Return on equity TTM	99.58%
Profit margin	58.79%
Book value	$1.874
Market capitalisation	USD$288.1 million

TTM: trailing 12 months

Shorting Co-Diagnostics shares

There are currently 6.8 million Co-Diagnostics shares held short by investors – that's known as Co-Diagnostics's "short interest". This figure is 6.5% down from 7.3 million last month.

There are a few different ways that this level of interest in shorting Co-Diagnostics shares can be evaluated.

Co-Diagnostics's "short interest ratio" (SIR)

Co-Diagnostics's "short interest ratio" (SIR) is the quantity of Co-Diagnostics shares currently shorted divided by the average quantity of Co-Diagnostics shares traded daily (recently around 1.4 million). Co-Diagnostics's SIR currently stands at 4.82. In other words for every 100,000 Co-Diagnostics shares traded daily on the market, roughly 4820 shares are currently held short.

However Co-Diagnostics's short interest can also be evaluated against the total number of Co-Diagnostics shares, or, against the total number of tradable Co-Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Co-Diagnostics's short interest could be expressed as 0.23% of the outstanding shares (for every 100,000 Co-Diagnostics shares in existence, roughly 230 shares are currently held short) or 0.231% of the tradable shares (for every 100,000 tradable Co-Diagnostics shares, roughly 231 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Co-Diagnostics.

Find out more about how you can short Co-Diagnostics stock.

Co-Diagnostics share dividends

We're not expecting Co-Diagnostics to pay a dividend over the next 12 months.

Co-Diagnostics share price volatility

Over the last 12 months, Co-Diagnostics's shares have ranged in value from as little as $1.07 up to $29.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Co-Diagnostics's is -1.7732. This would suggest that Co-Diagnostics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Co-Diagnostics has bucked the trend.

Co-Diagnostics overview

Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.

Frequently asked questions

• What percentage of Co-Diagnostics is owned by insiders or institutions?

  Currently 6.517% of Co-Diagnostics shares are held by insiders and 33.013% by institutions.

• How many people work for Co-Diagnostics?

  Latest data suggests 39 work at Co-Diagnostics.

• When does the fiscal year end for Co-Diagnostics?

  Co-Diagnostics's fiscal year ends in December.

• Where is Co-Diagnostics based?

  Co-Diagnostics's address is: 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109

• What is Co-Diagnostics's ISIN number?

  Co-Diagnostics's international securities identification number is: US1897631057

• What is Co-Diagnostics's CUSIP number?

  Co-Diagnostics's Committee on Uniform Securities Identification Procedures number is: 189763105